Background: Myocardial fibrosis is one of the mechanisms underlying left ventricular (LV) dysfunction in obese patients and may result from dysregulation of extracellular matrix (ECM) turnover. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) represent a regulatory system playing a crucial role in ECM metabolism. Objectives: We sought to assess plasma levels of MMP-2, MMP-9, TIMP-1 and TIMP-2 in obese young women and to evaluate the association between MMP/TIMP system components and LV function in this population. Design: Prospective, cross-sectional study. Setting: University hospital. Patients: Seventy-one women aged o35 years with body mass index 430 kg m À2 and 30 healthy slim female controls. Main outcome measures: Plasma MMP-2, MMP-9, TIMP-1 and TIMP-2 measurements and echocardiographic studies, including LV strain/strain rate evaluation. Results: We demonstrated increased levels of MMP-9 and TIMP-1 and decreased MMP-2 in the obese population. LV dysfunction shown in patients with obesity was characterized by significantly lower values of strain/strain rate parameters. Plasma MMP-2 correlated positively and TIMP-1 negatively with systolic strain (r ¼ 0.39, Po0.001 and r ¼ À0.40, Po0.001, respectively), peak systolic strain rate (r ¼ 0.38, Po0.001 and r ¼ À0.27, Po0.03, respectively) and peak early diastolic strain rate (r ¼ 0.40, Po0.001 and r ¼ À0.24, Po0.05, respectively). Plasma MMP-2, fasting insulin and body mass index proved the only independent determinants of strain/strain rate parameters of LV systolic and diastolic performance in obese subjects. Conclusions: In premenopausal obese women (1) plasma MMP/TIMP profile is altered, (2) abnormalities of LV function are related to the changes in the MMP/TIMP system that might promote attenuated ECM degradation, mainly to the downregulation of MMP-2.
Introduction
In recent years, obesity seems to be an increasing epidemiologic problem both in the developed and developing societies worldwide. 1 Obesity is frequently linked to major cardiovascular risk factors such as hypertension or diabetes; however, these comorbidities notwithstanding, it is also recognized as an entity predisposing to heart failure. There is growing evidence from epidemiologic studies that obesity is more common in women than in men and relative risk of heart failure is greater in obese female subjects than in their male counterparts. 2 In the pathogenesis of cardiac dysfunction in obese patients, a number of underlying mechanisms are considered, including myocardial fibrosis. Matrix metalloproteinases (MMPs)Fa series of zinc-dependent proteolytic enzymesFand their natural tissue inhibitors (TIMPs) represent a regulatory system implicated in extracellular matrix (ECM) turnover and thereby play a critical role in the development of interstitial fibrosis. 3, 4 Observations in hypertension, hypertrophic and dilated cardiomyopathy, coronary artery disease and diabetes revealed some associations between plasma levels of MMPs and TIMPs and cardiac morphology and function. [5] [6] [7] [8] [9] [10] Previous experimental studies indicate that fat tissue is a biological compartment of increased ECM metabolism and overproduction of many components of the MMP/TIMP system. 11, 12 To date, activation of MMPs and TIMPs in obesity has not been studied extensively on clinical grounds nor has its relation to left ventricular (LV) performance been estimated in obese persons. Against this background, we sought (1) to assess plasma levels of MMP-2 and MMP-9 and TIMP-1 and TIMP-2 in obese young women without other concomitant diseases and (2) to evaluate the association between the aforementioned MMP/TIMP system components and LV function in this population.
Methods
Seventy one women aged o35 years with body mass index 430 kg m
À2
, referred to the university hospital from general practice and specialist clinics for management of obesity, were prospectively enrolled into the study between February 2004 and July 2006. The referent group consisted of 30 healthy age-matched slim female volunteers (body mass index range: 17.6-21.5 kg m À2 ), recruited from the community. Premenopausal status was confirmed on the basis of serum follicular-stimulating hormone levels o30 mIU ml
À1
, estradiol levels 430 pg ml À1 and regular menstrual cycles within 1 year before including into the study. 13 All subjects underwent a clinical history and medical evaluation, including routine blood analysis, lipid profile, a 75 g oral glucose tolerance test, electrocardiogram and echocardiography. Exclusion criteria were any heart disease, hypertension, diabetes mellitus, thyroid and renal diseases, obstructive sleep apnea, pregnancy or breast-feeding, cigarette smoking, chronic alcohol consumption or current use of any medications. All subjects were informed regarding the purpose of the study and provided written informed consent. Investigations were in accordance with the Declaration of Helsinki and were approved by the local ethics committee. We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research.
Blood assays
Blood samples were obtained in the early follicular phase (2-5 days) of the menstrual cycle between 0800 and 0900 hours after 12 h fast and a 30 min resting in the supine position. Serum glucose was determined by enzymatic assay (Dade Behring Inc., Newark, DE, USA). Serum insulin was measured using a chemiluminescent enzyme immunoassay (Immulite 2000; Diagnostic Products Corp., Los Angeles, CA, USA). The homeostasis model assessment (homeostasis model assessment of insulin resistance (HOMA IR))Fan index of insulin resistance was calculated as fasting insulin Â fasting glucose/22.5. Plasma MMP-2 and MMP-9 and TIMP-1 and TIMP-2 levels were quantified by a sandwich enzyme immunoassay technique using commercially available kits from R&D Systems Inc. (Minneapolis, MN, USA). Intra-and inter-assay coefficients of variation were 4.2 and 6.9% for MMP-2, 2.1 and 6.8% for MMP-9, 3.9 and 4.5% for TIMP-1, and 4.5 and 6.3% for TIMP-1.
Serum C-reactive protein was estimated by a particleenhanced immunonephelometry (Dade Behring Diagnostics, Marburg, Germany) with a detection threshold of 0.175 mg l
À1
and intra-and inter-assay coefficients of variation 2.3-4.4 and 2.1-5.7%, respectively.
Echocardiography
Echocardiographic imaging was performed using GE Vingmed System Five (Horten, Norway) machine with a phased array 2.5 MHz multifrequency transducer.
Conventional echocardiography. Left ventricular and left atrial dimensions and wall thicknesses were measured from two-dimensionally targeted M-mode tracings, according to the recommendations of the American Society of Echocardiography.
14 LV mass was calculated using the Devereuxmodified American Society of Echocardiography cube formula and indexed to height to the power of 2.7 to obtain the LV mass index. 15 LV hypertrophy was defined as LV mass index 447 g m À2. 7 . LV end-diastolic and end-systolic volumes and ejection fraction were estimated by a modified Simpson's biplane method. LV end-diastolic volume was normalized for body surface area to achieve LV end-diastolic volume index. Pulsed wave Doppler recordings of the LV inflow were obtained from the apical four-chamber view with the sample volume placed between the tips of the mitral leaflets. The following parameters were assessed: peak early and late diastolic flow velocity, the ratio of peak early and late diastolic flow velocities and deceleration time of early diastolic flow wave.
Tissue Doppler imaging. To evaluate LV longitudinal function, real-time two-dimensional color Doppler myocardial imaging data were recorded in the apical four-chamber view. The width of the image sector and the depth of the imaging were adjusted to achieve a frame rate 4180 Hz. Pulse repetition frequency was set at the lowest value without aliasing. The sampling window was positioned as parallel as possible to the myocardial segment of interest to ensure the insonation angle did not exceed 201. The acquired data were stored in a cine-loop format and were transferred to dedicated software (Echopac 6.4.2; General Electric, Horten, Norway, and SPEQLE 4.7.0, KU Leuven, Leuven, Belgium) for subsequent off-line analysis. The region of interest was MMPs/TIMPs and cardiac function in obesity W Kosmala et al continuously positioned by manual tracking in the midmyocardial layer of each segment during the heart cycle.
Myocardial deformation. Left ventricular myocardial deformation curves were derived from the basal, mid and apical segments of the interventricular septum and lateral wall. The strain rate was assessed from the spatial velocity gradient over a computation area of 10 mm. Subsequently, strain rate profiles were integrated over time to obtain the natural strain curves using end-diastole defined to occur at the R-peak of electrocardiogram as the reference point. To specify end-systole, the timing of the aortic valve closure was established using pulsed Doppler blood pool tracings derived from the cardiac cycles with the same R-R interval as the curve evaluated. The analysis of LV deformation curves included the following variables: systolic strain identified as the amount of deformation measured between end-diastole and end-systole, peak systolic strain rate and peak early diastolic strain rate ( Figure 1 ).
Myocardial velocities. Regional myocardial velocity curves were extracted from color Doppler data acquired in the basal segments of the interventricular septum and lateral wall to assess peak early diastolic velocity.
Pulsed-wave tissue Doppler recordings of the septal and lateral portion of the mitral annulus were used for the measurement of peak early diastolic mitral annular velocity. The ratio of mitral inflow early diastolic velocity to the average peak early diastolic velocity from both sides of mitral annulus was computed to approximate LV filling pressure.
All strain, strain rate and myocardial velocity profiles were averaged over three consecutive heart cycles. The results are expressed as the average values from all segments subjected to evaluation.
Statistical analysis
Data are presented as mean ± s.d. for normal and median (interquartile range) for skewed distribution. Group comparisons were carried out by a two-sided Student's t-test after evaluation of the homogeneity of variances by the Levene's test. The associations between variables were assessed with the use of the Pearson correlation coefficient and stepwise multiple regression analysis. Skewed variables were analyzed as log-transformed values. All calculations were performed with standard statistical software (Statistica for Windows 7, StatSoft Inc., Tulsa, OK, USA). The level of statistical significance was set at P-value o0.05. Table 1 summarizes clinical data of the studied population. The average duration of obesity was 12.6 ± 5.7 years. By definition, body mass index, as well as other parameters directly related to the excess of adipose tissueFwaist circumference and waist-to-hip ratioFwas significantly higher in women with obesity. Although no obese female subject had an established diagnosis of hypertension, systolic blood pressure was higher in this group as compared to the controls. Similarly, fasting glucose levels were not Figure 1 Examples of LV myocardial deformation curves from the basal septal segment (the apical four-chamber view). RV, right ventricle; LV, left ventricle; RA, right atrium; LA, left atrium; ES, end-systole; SRe, peak early diastolic strain rate; SRs, peak systolic strain rate. The group with obesity demonstrated increased HOMA IR and fasting insulin, indicating impaired insulin sensitivity and elevated C-reactive protein, which reflects enhanced systemic inflammatory reaction.
Results

Patient characteristics
Echocardiography
No study participant was excluded from the echocardiographic analysis because of poor imaging quality. Nevertheless, although great care was taken during acquisition, 7% of all LV segments were disqualified from further evaluation due to unreliable interpretation of myocardial velocity and deformation profiles resulting from artifacts, poor signal-tonoise ratio or inadequate angle of insonation.
LV structure. Obese female subjects exhibited significantly higher values of LV end-diastolic dimension, LV mass index and left atrial dimension than that of their peers from the control group (Table 2) . LV hypertrophy was found in 22 patients with obesity and in no healthy control.
LV systolic function. Lower values of myocardial deformation indicesFstrain and peak systolic strain rate in the obese female subjects than in the controlsFwere indicative of the impairment of LV systolic function. The parameter of conventional echocardiographyFLV ejection fractionFwas similar between both groups (Table 2) .
LV diastolic function. Abnormalities of LV diastolic performance in patients with obesity were evidenced by reduced peak early diastolic strain rate and peak early diastolic velocity and increased ratio of mitral inflow early diastolic velocity to the average peak early diastolic velocity from both sides of mitral annulus. Conventional load-dependent echocardiographic indicesFthe ratio of peak early and late diastolic flow velocities and deceleration time of early diastolic flow waveFdid not differ significantly between women with and without obesity ( Table 2) .
Reproducibility of measurements.
All off-line analyses were performed by one observer (WK) blinded to the patients' clinical data, and intraobserver variability estimated in 15 consecutive patients was 0.2 ± 1.9% for strain, 0.1 ± 0.17 s À1 for peak systolic strain rate, 0.1±0.20 s À1 for peak early diastolic strain rate and 0.1 ± 0.4 cm s À1 for peak early diastolic velocity.
MMP and TIMP plasma profiles
Compared to the slim controls, the group of obese female subjects presented significantly higher MMP-9 and TIMP-1 and lower MMP-2 levels. TIMP-2 concentration was not statistically different between both groups ( Figure 2 ). The plots of peak systolic and early diastolic strain rate and MMP/TIMP parameters versus body mass index are presented in Figure 3 .
Interrelations
In the studied population with obesity, plasma MMP-9 and TIMP-1 were positively associated with body mass index (r ¼ 0.30, Po0.01 and r ¼ 0.25, Po0.04, respectively). There was no relation between any of the evaluated MMP/TIMP system components and estimates of insulin resistance (HOMA IR, fasting insulin) or inflammatory activation (C-reactive protein).
Significant correlations of LV function indices in obese women are presented in Table 3 and Figure 4 . In multivariate forward stepwise regression models (considering in addition to factors in Table 3 , also other parameters significantly associated with a dependent variable, such as age, blood pressure, LV mass index, MMP-9 and TIMP-2 levels), only body mass index, fasting insulin and plasma MMP-2 remained independent correlates of LV systolic and diastolic function indices (Table 4) .
Discussion
The main clinical findings of the present study are that in premenopausal obese women (1) the plasma MMP/TIMP profile is altered, as seen in reduced MMP-2 and elevated MMP-9 and TIMP-1 levels, (2) abnormalities of LV function are related to the changes in the MMP/TIMP system that might promote attenuated ECM degradation, mainly to the downregulation of MMP-2. Abbreviations: A, peak late diastolic mitral flow velocity; DT, deceleration time of early diastolic mitral flow; E, peak early diastolic mitral flow velocity; E 0 , peak early diastolic mitral annular velocity; Em, peak early diastolic myocardial velocity; LV, left ventricular; LVEDVI, left ventricular end-diastolic volume index; NS, no significant difference; SRe, peak early diastolic strain rate; SRs, peak systolic strain rate.
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MMP and TIMP plasma profiles
Metalloproteinases and their tissue inhibitors regulate catabolism of ECM both in normal conditions and in pathological settings. Substrates for MMP-2 and MMP-9 are basement membrane proteins such as elastin, fibronectin, laminin and gelatin as well as fibrillar collagen. TIMPs are able to selectively inactivate MMPs, including MMP-2 and MMP-9 in a 1:1 relationship, although the affinity to do this may differ depending on the type of the molecule. 12, 16, 17 The interplay between MMPs and TIMPs is crucial for the maintenance of ECM integrity and function. The imbalance in the MMP/TIMP system may provide a pathophysiological background for a variety of multiple disease states. Metalloproteinases and TIMPs are synthesized in a variety of tissues. Altered levels of MMPs and TIMPs were demonstrated both in affected organs and in peripheral blood in patients with coronary artery disease, hypertension, aortic stenosis, dilated cardiomyopathy, diabetes mellitus, polycystic ovary syndrome, neoplasmatic diseases, rheumatoid arthritis, bronchial asthma and hepatic disorders. 5, 8, 10, [18] [19] [20] [21] [22] [23] Remarkably, the results of the observations concerning MMP/TIMP changes are not uniformly concordant, especially in cardiovascular pathologies, depending on the patients' recruitment process, concomitant pharmacotherapy or the method of measurements of MMP and TIMP levels. Apart from this, the activation of the ECM proteolytic system is not homogenous even in patients with the same disease, which is due to different and not fully recognized regulatory pathways for MMPs and TIMPs.
Previous studies in obese cohorts demonstrated increased monocyte mRNA expression and plasma levels of MMP-9, 24 as well as its marked decline accompanying body mass reduction. 25 The recently published report revealed in the population of children and young adolescent with obesity elevated circulating MMP-9 and TIMP-1. 26 In another paper, sleep apnea syndrome was a condition enhancing serum levels of MMP-9 in obese subjects. 22 The experimental studies focused mainly on the adipose tissue expression of MMPs and their inhibitors showing different regulation patterns of the MMP/TIMP system and providing evidence for its involvement in adipocyte differentiation and fat tissue growth and remodeling.
11,12
The present study has demonstrated alterations of the plasma MMP/TIMP profile in a population of young obese otherwise healthy women. Clearly, the decreased MMP-2 and increased TIMP-1 revealed in our investigations may facilitate ECM accumulation, whereas elevated MMP-9 may contribute to enhanced ECM proteolysis. On the other hand, it is worth noting that although both MMP-2 and MMP-9 catabolize the same protein substrates, MMP-9 has substantially lower activity than MMP-2. In addition, MMP-9 is involved in promoting transforming growth factor-b1 (TGF-b1) and other proteins with profibrotic properties. 5, 27 One can only speculate about derangements of ECM MMPs/TIMPs and cardiac function in obesity W Kosmala et al composition that might result from observed changes in MMP/TIMP profile. Nonetheless, without a direct insight into histopathology and evaluation of other constituents of the proteolytic system, the prediction of the net effect of the alterations demonstrated in MMPs/TIMPs profile on ECM turnover is uncertain. Figure 3 Distribution of peak systolic and early diastolic strain rate and plasma MMP-2 and MMP-9 and TIMP-1 and TIMP-2 levels in relation to body mass index in obese women and slim controls (right and left part of each diagram, respectively). SRs, peak systolic strain rate; SRe, peak early diastolic strain rate; MMP-2, matrix metalloproteinase 2; MMP-9, matrix metalloproteinase 9; TIMP-1, tissue inhibitor of metalloproteinase 1; TIMP-2, tissue inhibitor of metalloproteinase 2; BMI, body mass index. Abbreviations: Em, peak early diastolic myocardial velocity; HOMA IR, homeostasis model assessment of insulin resistance; MMP-2, matrix metalloproteinase 2; SRe, peak early diastolic strain rate; SRs, peak systolic strain rate; TIMP-1, tissue inhibitor of metalloproteinase 1.
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The complexity of functional properties of MMP/TIMP system poses some limitations on concluding about the exact outcome of its activity. MMPs, besides their ability to cleave a variety of ECM components, may also influence the release and bioavailability of a number of growth factors and cytokines, which in turn might modulate MMPs expression. Similarly, the biological effects of TIMPs are not confined to their MMPs-inhibiting action and, in addition, include the regulation of cell proliferation and apoptosis. 11, 12 Together, the obesity-associated changes in MMPs/TIMPs profile may not simply translate into the clinical consequences expected from the theoretical assumptions considering only the basic modes of MMPs and TIMPs activity. The significant positive correlations between body mass index and plasma MMP-9 and TIMP-1 found in our study might support the concept of adipose tissue being an important source of some MMP/TIMP system elements. Moreover, adipose tissue might store and secrete other factors that are involved in ECM metabolism, such as TGF-b1 and angiotensinogen, with its subsequent conversion to angiotensin II and stimulation of aldosterone. The fibrogenic effect of angiotensin II is largely accounted for by the upregulation of TGF-b1 via the angiotensin II receptor type 1 activation. 28 TGF-b1 and its downstream mediator, connective tissue growth factor, both enhance fibrous tissue formation and diminish its degradation, hence increasing perivascular and interstitial fibrosis, including also myocardium.
29
Relationships between MMP and TIMP plasma profiles and LV function As previously evidenced, myocardial fibrosis may underlie both diastolic and systolic dysfunction of the heart. 30, 31 The activity of particular components of the MMP/TIMP system might reflect shifts in the ECM metabolism, including collagen homeostasis, thus, being related to the extent of interstitial fibrosis. The relationships between circulating MMP/TIMP levels and LV function have been assessed in a number of previous studies in multiple subsets of patients with hypertension, myocardial infarction, diabetes mellitus, hypertrophic or dilated cardiomyopathy, exhibiting frequently incoherent and conflicting results. [5] [6] [7] [8] 10, [32] [33] [34] In different clinical settings and experimental protocols both TIMPs, especially TIMP-1, and MMPs, particularly MMP-1 and MMP-2, proved to be markers of LV systolic and diastolic dysfunction.
In the population of obese women, we found significant univariate correlations between the parameters of LV functionFsystolic strain, peak systolic and early diastolic strain rateFand plasma levels of MMP-2 and TIMP-1; however, only MMP-2 was, besides fasting insulin (a measure of insulin resistance) and body mass index, an independent determinant of LV systolic and diastolic abnormalities. Correspondingly, similar findings were reported from the study in hypertrophic cardiomyopathy, in which suppression of serum MMP-2 activity was related to the impairment of LV diastolic performance 7 aforementioned.
Myocardial fibrosis, in addition to cardiotoxicity of accumulated lipids, insulin resistance with altered metabolism of cardiomyocytes and trophic effects of hyperinsulinemia or neurohormonal and cytokine upregulation, is postulated as one of the putative mechanisms of LV dysfunction in obese subjects. 31, [35] [36] [37] [38] As mentioned above, Figure 4 Association of plasma MMP-2 level with SRs (a) and SRe (b) in obese women. MMP-2, matrix metalloproteinase 2; SRs, peak systolic strain rate; SRe, peak early diastolic strain rate. MMPs/TIMPs and cardiac function in obesity W Kosmala et al a pivotal reason of obesity-related cardiac fibrosis is thought to be a local activation of the renin-angiotensin-aldosterone system and TGF-b1 in the myocardium, which in turn modulate qualitative and quantitative changes in collagen content. 27, 39 Notwithstanding, it should be stressed that in the present study we used plasma MMP and TIMP levels as surrogate markers, which do not necessarily represent myocardial activation of the ECM proteolytic system. Circulating MMPs and TIMPs in obesity may be released both from cardiac and non-cardiac sources, including adipose tissue, vasculature and peripheral blood neutrophils and monocytes. 11, 22, 24 Thus, our data must be interpreted with caution. We demonstrated the association of plasma MMP/TIMP profile alterations possibly favoring collagen accumulation with indices of cardiac dynamics; however, we cannot clearly relate this finding to the increase in myocardial fibrosis. Decreased plasma MMP-2 being an independent correlate of LV dysfunction indices might suggest such a possibility; nonetheless, these are only speculations and actually warrant further investigations.
Although we failed to demonstrate the abdominal fat distribution indices, namely waist-to-hip ratio and waist circumference, to be independent correlates of LV function in the studied population with obesity, it is well established that visceral fat is involved in the production of biologically active compounds including, besides the proteins responsible for myocardial fibrosis, also cardiodepressant factors, such as tumor necrosis factor-a and interleukin-6, which can be associated with the development of myocardial function impairment. 40 The lifestyle modifications including low-caloric diet and exercise training with concomitant weight loss in the cohort of obese men with high prevalence of metabolic syndrome factors resulted in a significant decrease in serum MMP-9. 41 The effect of weight reduction on MMP/TIMP system components in the obese female population and whether this could contribute to LV function improvement need to be clarified in the future studies.
The increased level of C-reactive protein in the studied group, which indicates a subclinical inflammatory process, has not been related independently to the parameters of LV performance, even though inflammation is considered to contribute to LV dysfunction in obesity. 24 It is likely that C-reactive protein might not be an appropriate marker in searching for such associations.
Conclusion
The present study documented in a population of obese premenopausal women an altered plasma MMP/TIMP profile as well as its association with concurrent asymptomatic LV dysfunction. The ECM proteolytic system might conceivably represent a potential therapeutic target in patients with obesity, relevant for the prevention of subsequent development of clinically overt heart disease.
Limitations
The limitations of the current study are as follows: (1) we have not verified a coronary status in the studied population; however, we have dismissed it as a significant contributor on account of the young age of study participants, the absence of any symptoms and no history of premature atherosclerosis in the family. (2) A cross-sectional, not longitudinal, design of the study makes concluding about the casual nature of demonstrated relations impossible. (3) Because of the multitude of conditions associated with obesity, the results of the present study cannot be simply extrapolated to other obese cohorts.
